NeuroPace (NPCE) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
NeuroPace Reports Second Quarter 2022 Financial Results and Provides a Business Update
August 11, 2022 4:02 PM EDTMOUNTAIN VIEW, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ending June 30, 2022.
Recent Highlights
Announced exclusive U.S. distribution agreement with DIXI Medical to sell its stereo EEG electrodes to Epilepsy Monitoring Units (EMUs)Completed sales team expansion initiativeBegins enrollment in the NAUTILUS study for primary generalized epilepsyTotal revenue of $10.2 million for the second quarter of 2022Initial implant... More